The district court determined that the patent is invalid on two separate grounds – lack of written description and lack of enablement, the company said.
Lannett and HEC will, in exchange for its financial contribution, receive a sub-license to a licensing arrangement between Ypsomed and Sanofi-Aventis Deutschland GmbH.
Buphenyl is used as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamyl phosphate synthetase.
